BioSilta, a spin-out company from the University of Oulu, develops and markets advanced microbial growth systems and CyDisCo protoplast based production technology. BioSilta’s growth system products are based on the company’s proprietary EnBase® technology offering a novel approach to control the feeding, and thereby growth rate, of microbial cultures. BioSilta’s products have been shown to increase protein yields up to 100-fold and improve protein functionality. Products are supplied as presterilized tablet format. BioSilta is located in Cambridge, UK and Oulu, Finland.bridge, UK and Oulu, Finland.
Herantis Pharma Oyj
Herantis is a clinical-stage pharmaceutical development company developing drugs for central nervous system, lymphatic and inflammatory diseases. The company’s lead products target Parkinson’s disease, secondary lymphedema and dry eye. Herantis was formed by combining two Finnish pharmaceutical development companies, Hermo Pharma and Laurantis Pharma, in April 2014. Herantis completed initial public offering in June 2014. The company’s shares are listed on the First North Finland marketplace of NASDAQ OMX Helsinki. Herantis is located in Helsinki, Finland.
Priaxon is a drug discovery and development company focusing on small molecule therapeutics against hard-to-drug protein-protein interaction targets. Priaxon uses the proprietary technology platform PriaXplore® to generate value by developing and out-licensing projects in different stages, reaching from early lead classes of new chemical entities to candidates in clinical development. Priaxon has made partnering deals among others with Boehringer Ingelheim and GlaxoSmithKline. Priaxon is located in Munich, Germany.
Medtentia International Ltd Oy
Medtentia is a medical device company developing novel mitral (heart) valve repair products. Medtentia’s products – transcatheter mitral repair system (CathHELIX) and surgical annuloplasty ring – are based on the company’s proprietary helix concept and have the potential to significantly reduce the invasiveness, operation time and morbidity currently associated with mitral valve repair operations. Medtentia has successfully completed the first phase of clinical studies evaluating helix ring in patients undergoing mitral valve repair surgery and is in the late pre-clinical development phase with CathHELIX. Medtentia is located in Espoo, Finland.
Onbone is a medical device company developing and marketing Woodcast® products for orthopaedic and traumatology use. Woodcast® is manufactured from clean wood and biodegradable plastic. It is completely non-toxic and perfectly mouldable & remouldable thus being suitable for all casting work. In addition to being non-toxic and clean, Woodcast® is fast and easy to work with, the pre-warmed material can be moulded to any anatomical shape and there is no need to remove Woodcast® before X-ray imaging. Onbone is located in Helsinki, Finland.